Paper39720956
Cancer vaccines: an update on recent achievements and prospects for cancer therapy.
Chekaoui A and 13 others. Clin Exp Med, 2024. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Cancer vaccines: an update on recent achievements and prospects for cancer therapy. Papers, record 39720956. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39720956
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cancer Vaccines | Major topic |
| Neoplasms | Major topic |
| Immunotherapy | Major topic |
| Humans | |
| Immune Checkpoint Inhibitors | |
| Clinical Trials as Topic | |
| Antigens, Neoplasm |
Source PubMed
Grants10
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2022/47/D/NZ7/03212 | Narodowe Centrum Nauki | PubMed | ||
| 2022/47/D/NZ7/03212 | Narodowe Centrum Nauki | PubMed | ||
| 2022/47/D/NZ7/03212 | Narodowe Centrum Nauki | PubMed | ||
| 2022/47/D/NZ7/03212 | Narodowe Centrum Nauki | PubMed | ||
| GAR- O_STARS_MUR22_01 | Università degli Studi di Padova | PubMed | ||
| CN00000041 | European Commission | PubMed | ||
| CN00000041 | European Commission | PubMed | ||
| CN00000041 | European Commission | PubMed | ||
| 0258/L-14/2023 | Narodowe Centrum Badań i Rozwoju | PubMed | ||
| BW-3/2024 | National Institute of Public Health NIH - National Research Institute | PubMed |
Source PubMed
References220
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37409952 | Updating the Definition of Cancer. | Mol Cancer Res | 2023 | https://conductscience.org/library/papers/37409952 | PubMed |
| 2 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 3 | 33419794 | Chemoradiotherapy in Cancer Treatment: Rationale and Clinical Applications. | Anticancer Res | 2021 | https://conductscience.org/library/papers/33419794 | PubMed |
| 4 | 35906199 | Radiotherapy combined with immunotherapy: the dawn of cancer treatment. | Signal Transduct Target Ther | 2022 | https://conductscience.org/library/papers/35906199 | PubMed |
| 5 | 34408877 | New approaches and procedures for cancer treatment: Current perspectives. | SAGE Open Med | 2021 | https://conductscience.org/library/papers/34408877 | PubMed |
| 6 | 29230567 | Cancer nanomedicine: a review of recent success in drug delivery. | Clin Transl Med | 2017 | https://conductscience.org/library/papers/29230567 | PubMed |
| 7 | 25622193 | Innate immune recognition of cancer. | Annu Rev Immunol | 2015 | https://conductscience.org/library/papers/25622193 | PubMed |
| 8 | 38406616 | I. IDC Key-note Lecture: Trained immunity: a memory for innate host defense. | J Stem Cells Regen Med | 2023 | https://conductscience.org/library/papers/38406616 | PubMed |
| 9 | 32612154 | The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. | Cell Mol Immunol | 2020 | https://conductscience.org/library/papers/32612154 | PubMed |
| 10 | 35759082 | Immunotherapy: an alternative promising therapeutic approach against cancers. | Mol Biol Rep | 2022 | https://conductscience.org/library/papers/35759082 | PubMed |
| 11 | 31754328 | Current Progress in CAR-T Cell Therapy for Solid Tumors. | Int J Biol Sci | 2019 | https://conductscience.org/library/papers/31754328 | PubMed |
| 12 | 36477638 | Development of therapeutic vaccines for the treatment of diseases. | Mol Biomed | 2022 | https://conductscience.org/library/papers/36477638 | PubMed |
| 13 | 33515252 | The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/33515252 | PubMed |
| 14 | 33064982 | Why and How Vaccines Work. | Cell | 2020 | https://conductscience.org/library/papers/33064982 | PubMed |
| 15 | 12974478 | Cancer vaccines: between the idea and the reality. | Nat Rev Immunol | 2003 | https://conductscience.org/library/papers/12974478 | PubMed |
| 16 | 37820582 | The cancer-immunity cycle: Indication, genotype, and immunotype. | Immunity | 2023 | https://conductscience.org/library/papers/37820582 | PubMed |
| 17 | 25795789 | Tumor-infiltrating dendritic cells in cancer pathogenesis. | J Immunol | 2015 | https://conductscience.org/library/papers/25795789 | PubMed |
| 18 | 12871638 | Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. | Immunity | 2003 | https://conductscience.org/library/papers/12871638 | PubMed |
| 19 | 1083422 | Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. | J Exp Med | 1976 | https://conductscience.org/library/papers/1083422 | PubMed |
| 20 | 18799145 | Cancer immunotherapy by dendritic cells. | Immunity | 2008 | https://conductscience.org/library/papers/18799145 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41945934 | Cancer Vaccines: Mobilizing Immunity for Targeted Cancer Therapy. | Asian Pac J Cancer Prev | 2026 | https://conductscience.org/library/papers/41945934 | PubMed |
| 41746058 | Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/41746058 | PubMed |
| 41302542 | In Vivo Behavior of Biomimetic Nanoparticles: Strategies for Clearance Avoidance, Targeting, and Functional Delivery. | Molecules | 2025 | https://conductscience.org/library/papers/41302542 | PubMed |
| 41182668 | Dynamic 3D microfluidic platform for exploring combined targeted therapy, chemotherapy, and virotherapy delivery in ovarian cancer. | Drug Deliv Transl Res | 2026 | https://conductscience.org/library/papers/41182668 | PubMed |
| 41002395 | mRNA Multipeptide-HLA Class II Immunotherapy for Melanoma. | Cells | 2025 | https://conductscience.org/library/papers/41002395 | PubMed |
| 40992760 | Cancer Stem Cells Decide the Fate of Cancer Immunotherapy by Remodeling Tumor Microenvironment. | Cancer Control | 2025 | https://conductscience.org/library/papers/40992760 | PubMed |
| 40725126 | Strategic Advances in Targeted Delivery Carriers for Therapeutic Cancer Vaccines. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40725126 | PubMed |
| 40507776 | RNA Through Time: From the Origin of Life to Therapeutic Frontiers in Transcriptomics and Epitranscriptional Medicine. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40507776 | PubMed |
| 40314865 | The evolving landscape of oncolytic virus immunotherapy: combinatorial strategies and novel engineering approaches. | Med Oncol | 2025 | https://conductscience.org/library/papers/40314865 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39720956
GET https://conductscience.org/api/papers/v1/39720956/references?page=2